Levodopa use in Denmark:high levels in Greenland and the Faroe Islands

Levodopa (LD) sales from wholesalers to pharmacies during the periods, 1977–1989 in Denmark, 1981–1989 in Greenland, and April 1988–May 1989 in Danish counties and the Faroe Islands, were evaluated using a reported method and a procedure expressly developed for assessment of random variation compara...

Full description

Bibliographic Details
Published in:Acta Neurologica Scandinavica
Main Authors: de Pedro‐Cuesta, J., Wermuth, L., Abraira, V., Stawiarz, L.
Format: Article in Journal/Newspaper
Language:English
Published: 1995
Subjects:
drug use
epidemiology
etiology
Parkinson's disease
quality control
therapy
Faroe Islands
Greenland
Online Access:https://portal.findresearcher.sdu.dk/da/publications/307b6209-a8c3-449b-8272-d2cf0786f0db
https://doi.org/10.1111/j.1600-0404.1995.tb00413.x
Description
Summary:Levodopa (LD) sales from wholesalers to pharmacies during the periods, 1977–1989 in Denmark, 1981–1989 in Greenland, and April 1988–May 1989 in Danish counties and the Faroe Islands, were evaluated using a reported method and a procedure expressly developed for assessment of random variation comparative levodopa use (LDU) measurements. The reference population for comparison of LDU was the Swedish from 1984. LDU diffusion had stabilized by 1989 in Denmark, but considerable annual increments of LD sales were still seen in Greenland in 1989. Crude LDU in Denmark and most Danish counties amounted to a level similar to that of Sweden. Adjustments for age and infant mortality rates, taken as an indicator of socioeconomic development, disclosed statistically significant twofold levels of LDU in the Faroe Islands and Greenland, and lowest LDU in urban regions. The social or biological factors underlying such differences in drug use remain unknown.

Similar Items